A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT)

Wenche Jy, Wei Wei Mao, Lawrence L. Horstman, Peter A. Valant, Yeon Ahn

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Heparin induced thrombocytopenia (HIT) is a well-known complication of heparin administration but usually resolves upon discontinuation without sequelae. However, a small proportion of HIT patients develop thrombosis associated with HIT, designated as HITT, which is often life-threatening and may lead to gangrene and amputations. Existing laboratory methods of confirming HIT/HITT do not distinguish between HIT and HITT. We report a flow cytometric assay of platelet activation marker CD62P to distinguish the effects of addition of HIT vs. HITT plasma to normal blood. Briefly, normal whole blood was incubated with platelet-poor plasma from 12 patients with HITT, 30 with HIT, and 65 controls, in presence and absence of heparin, and expression of CD62P was assayed by flow cytometry. When the ratios of fluorescent intensity of CD62P with heparin divided by that without heparin were compared, HITT plasma induced significantly higher ratios than HIT plasma (HITT ratios ~ 2.5 vs. HIT ratios ~ 1.2; p < 0.001). Eleven of 12 HITT patients were positive by this test but only 5 of 30 HIT patients were positive (p < 0.0005). In a case of HIT with silent thrombosis, this assay gave a positive results prior to clinically evident thrombosis. In conclusion, this method distinguishes HITT from HIT and may be clinically useful in the detection of HITT, allowing early intervention for preventing catastrophic thrombosis.

Original languageEnglish
Pages (from-to)1255-1259
Number of pages5
JournalThrombosis and Haemostasis
Volume82
Issue number4
StatePublished - Oct 20 1999

Fingerprint

P-Selectin
Platelet Activation
Thrombocytopenia
Heparin
Thrombosis
Gangrene
Amputation

Keywords

  • CD36
  • CD62
  • Drug-induced antibodies
  • Heparin
  • Heparin-induced thrombocytopenia
  • P-selectin
  • Platelet activation
  • Thrombocytopenia
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). / Jy, Wenche; Mao, Wei Wei; Horstman, Lawrence L.; Valant, Peter A.; Ahn, Yeon.

In: Thrombosis and Haemostasis, Vol. 82, No. 4, 20.10.1999, p. 1255-1259.

Research output: Contribution to journalArticle

@article{6aafa4c662974f3fa3d052ba9fca8ae5,
title = "A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT)",
abstract = "Heparin induced thrombocytopenia (HIT) is a well-known complication of heparin administration but usually resolves upon discontinuation without sequelae. However, a small proportion of HIT patients develop thrombosis associated with HIT, designated as HITT, which is often life-threatening and may lead to gangrene and amputations. Existing laboratory methods of confirming HIT/HITT do not distinguish between HIT and HITT. We report a flow cytometric assay of platelet activation marker CD62P to distinguish the effects of addition of HIT vs. HITT plasma to normal blood. Briefly, normal whole blood was incubated with platelet-poor plasma from 12 patients with HITT, 30 with HIT, and 65 controls, in presence and absence of heparin, and expression of CD62P was assayed by flow cytometry. When the ratios of fluorescent intensity of CD62P with heparin divided by that without heparin were compared, HITT plasma induced significantly higher ratios than HIT plasma (HITT ratios ~ 2.5 vs. HIT ratios ~ 1.2; p < 0.001). Eleven of 12 HITT patients were positive by this test but only 5 of 30 HIT patients were positive (p < 0.0005). In a case of HIT with silent thrombosis, this assay gave a positive results prior to clinically evident thrombosis. In conclusion, this method distinguishes HITT from HIT and may be clinically useful in the detection of HITT, allowing early intervention for preventing catastrophic thrombosis.",
keywords = "CD36, CD62, Drug-induced antibodies, Heparin, Heparin-induced thrombocytopenia, P-selectin, Platelet activation, Thrombocytopenia, Thrombosis",
author = "Wenche Jy and Mao, {Wei Wei} and Horstman, {Lawrence L.} and Valant, {Peter A.} and Yeon Ahn",
year = "1999",
month = "10",
day = "20",
language = "English",
volume = "82",
pages = "1255--1259",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT)

AU - Jy, Wenche

AU - Mao, Wei Wei

AU - Horstman, Lawrence L.

AU - Valant, Peter A.

AU - Ahn, Yeon

PY - 1999/10/20

Y1 - 1999/10/20

N2 - Heparin induced thrombocytopenia (HIT) is a well-known complication of heparin administration but usually resolves upon discontinuation without sequelae. However, a small proportion of HIT patients develop thrombosis associated with HIT, designated as HITT, which is often life-threatening and may lead to gangrene and amputations. Existing laboratory methods of confirming HIT/HITT do not distinguish between HIT and HITT. We report a flow cytometric assay of platelet activation marker CD62P to distinguish the effects of addition of HIT vs. HITT plasma to normal blood. Briefly, normal whole blood was incubated with platelet-poor plasma from 12 patients with HITT, 30 with HIT, and 65 controls, in presence and absence of heparin, and expression of CD62P was assayed by flow cytometry. When the ratios of fluorescent intensity of CD62P with heparin divided by that without heparin were compared, HITT plasma induced significantly higher ratios than HIT plasma (HITT ratios ~ 2.5 vs. HIT ratios ~ 1.2; p < 0.001). Eleven of 12 HITT patients were positive by this test but only 5 of 30 HIT patients were positive (p < 0.0005). In a case of HIT with silent thrombosis, this assay gave a positive results prior to clinically evident thrombosis. In conclusion, this method distinguishes HITT from HIT and may be clinically useful in the detection of HITT, allowing early intervention for preventing catastrophic thrombosis.

AB - Heparin induced thrombocytopenia (HIT) is a well-known complication of heparin administration but usually resolves upon discontinuation without sequelae. However, a small proportion of HIT patients develop thrombosis associated with HIT, designated as HITT, which is often life-threatening and may lead to gangrene and amputations. Existing laboratory methods of confirming HIT/HITT do not distinguish between HIT and HITT. We report a flow cytometric assay of platelet activation marker CD62P to distinguish the effects of addition of HIT vs. HITT plasma to normal blood. Briefly, normal whole blood was incubated with platelet-poor plasma from 12 patients with HITT, 30 with HIT, and 65 controls, in presence and absence of heparin, and expression of CD62P was assayed by flow cytometry. When the ratios of fluorescent intensity of CD62P with heparin divided by that without heparin were compared, HITT plasma induced significantly higher ratios than HIT plasma (HITT ratios ~ 2.5 vs. HIT ratios ~ 1.2; p < 0.001). Eleven of 12 HITT patients were positive by this test but only 5 of 30 HIT patients were positive (p < 0.0005). In a case of HIT with silent thrombosis, this assay gave a positive results prior to clinically evident thrombosis. In conclusion, this method distinguishes HITT from HIT and may be clinically useful in the detection of HITT, allowing early intervention for preventing catastrophic thrombosis.

KW - CD36

KW - CD62

KW - Drug-induced antibodies

KW - Heparin

KW - Heparin-induced thrombocytopenia

KW - P-selectin

KW - Platelet activation

KW - Thrombocytopenia

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0032863073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032863073&partnerID=8YFLogxK

M3 - Article

C2 - 10544909

AN - SCOPUS:0032863073

VL - 82

SP - 1255

EP - 1259

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -